Diabetic Macular Edema Treatment
Global Diabetic Macular Edema Treatment Market to Reach $4.5 Billion by 2027
In the changed post COVID-19 business landscape, the global market for Diabetic Macular Edema Treatment estimated at US$4 Billion in the year 2020, is projected to reach a revised size of US$4.5 Billion by 2027, growing at a CAGR of 1.9% over the analysis period 2020-2027. Anti-VEGF, one of the segments analyzed in the report, is projected to record a 2.2% CAGR and reach US$2.2 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Corticosteroid segment is readjusted to a revised 1.8% CAGR for the next 7-year period.
The U.S. Market is Estimated at $1.2 Billion, While China is Forecast to Grow at 1.5% CAGR
The Diabetic Macular Edema Treatment market in the U.S. is estimated at US$1.2 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$793.2 Million by the year 2027 trailing a CAGR of 1.5% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 1.8% and 1.3% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 1.4% CAGR.Other Products Segment to Record 1.3% CAGR
In the global Other Products segment, USA, Canada, Japan, China and Europe will drive the 1.3% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$513.1 Million in the year 2020 will reach a projected size of US$563.6 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets.
Select Competitors (Total 38 Featured) -
- Acucela Inc.
- Aerie Pharmaceuticals, Inc.
- Aerpio Pharmaceuticals
- Antisense Therapeutics Limited
- Araim Pharmaceuticals, Inc.
- BCN Peptides S.A.
- Biomar Microbial Technologies
- Charlesson LLC
- Coherus BioSciences
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.
The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.
Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.
- I. METHODOLOGY
- II. EXECUTIVE SUMMARY
- 1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Diabetic Macular Edema Treatment – Global Key Competitors Percentage Market Share in 2022 (E)
- Impact of Covid-19 and a Looming Global Recession
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
- 2. FOCUS ON SELECT PLAYERS
- 3. MARKET TRENDS & DRIVERS
- 4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Recent Past, Current & Future Analysis for Diabetic Macular Edema Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
- TABLE 2: World Historic Review for Diabetic Macular Edema Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 3: World 15-Year Perspective for Diabetic Macular Edema Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2021 & 2027
- TABLE 4: World Recent Past, Current & Future Analysis for Anti-VEGF by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
- TABLE 5: World Historic Review for Anti-VEGF by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 6: World 15-Year Perspective for Anti-VEGF by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
- TABLE 7: World Recent Past, Current & Future Analysis for Corticosteroid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
- TABLE 8: World Historic Review for Corticosteroid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 9: World 15-Year Perspective for Corticosteroid by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
- TABLE 10: World Recent Past, Current & Future Analysis for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
- TABLE 11: World Historic Review for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 12: World 15-Year Perspective for Other Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
- TABLE 13: World Diabetic Macular Edema Treatment Market Analysis of Annual Sales in US$ Million for Years 2012 through 2027
- III. MARKET ANALYSIS
- UNITED STATES
- Diabetic Macular Edema Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E)
- TABLE 14: USA Recent Past, Current & Future Analysis for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 15: USA Historic Review for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 16: USA 15-Year Perspective for Diabetic Macular Edema Treatment by Product - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroid and Other Products for the Years 2012, 2021 & 2027
- CANADA
- TABLE 17: Canada Recent Past, Current & Future Analysis for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 18: Canada Historic Review for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 19: Canada 15-Year Perspective for Diabetic Macular Edema Treatment by Product - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroid and Other Products for the Years 2012, 2021 & 2027
- JAPAN
- Diabetic Macular Edema Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E)
- TABLE 20: Japan Recent Past, Current & Future Analysis for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 21: Japan Historic Review for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 22: Japan 15-Year Perspective for Diabetic Macular Edema Treatment by Product - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroid and Other Products for the Years 2012, 2021 & 2027
- CHINA
- Diabetic Macular Edema Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E)
- TABLE 23: China Recent Past, Current & Future Analysis for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 24: China Historic Review for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 25: China 15-Year Perspective for Diabetic Macular Edema Treatment by Product - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroid and Other Products for the Years 2012, 2021 & 2027
- EUROPE
- Diabetic Macular Edema Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E)
- TABLE 26: Europe Recent Past, Current & Future Analysis for Diabetic Macular Edema Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
- TABLE 27: Europe Historic Review for Diabetic Macular Edema Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 28: Europe 15-Year Perspective for Diabetic Macular Edema Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2021 & 2027
- TABLE 29: Europe Recent Past, Current & Future Analysis for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 30: Europe Historic Review for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 31: Europe 15-Year Perspective for Diabetic Macular Edema Treatment by Product - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroid and Other Products for the Years 2012, 2021 & 2027
- FRANCE
- Diabetic Macular Edema Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E)
- TABLE 32: France Recent Past, Current & Future Analysis for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 33: France Historic Review for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 34: France 15-Year Perspective for Diabetic Macular Edema Treatment by Product - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroid and Other Products for the Years 2012, 2021 & 2027
- GERMANY
- Diabetic Macular Edema Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022 (E)
- TABLE 35: Germany Recent Past, Current & Future Analysis for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 36: Germany Historic Review for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 37: Germany 15-Year Perspective for Diabetic Macular Edema Treatment by Product - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroid and Other Products for the Years 2012, 2021 & 2027
- ITALY
- TABLE 38: Italy Recent Past, Current & Future Analysis for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 39: Italy Historic Review for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 40: Italy 15-Year Perspective for Diabetic Macular Edema Treatment by Product - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroid and Other Products for the Years 2012, 2021 & 2027
- UNITED KINGDOM
- Diabetic Macular Edema Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2022 (E)
- TABLE 41: UK Recent Past, Current & Future Analysis for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 42: UK Historic Review for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 43: UK 15-Year Perspective for Diabetic Macular Edema Treatment by Product - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroid and Other Products for the Years 2012, 2021 & 2027
- REST OF EUROPE
- TABLE 44: Rest of Europe Recent Past, Current & Future Analysis for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 45: Rest of Europe Historic Review for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 46: Rest of Europe 15-Year Perspective for Diabetic Macular Edema Treatment by Product - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroid and Other Products for the Years 2012, 2021 & 2027
- ASIA-PACIFIC
- Diabetic Macular Edema Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E)
- TABLE 47: Asia-Pacific Recent Past, Current & Future Analysis for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 48: Asia-Pacific Historic Review for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 49: Asia-Pacific 15-Year Perspective for Diabetic Macular Edema Treatment by Product - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroid and Other Products for the Years 2012, 2021 & 2027
- REST OF WORLD
- TABLE 50: Rest of World Recent Past, Current & Future Analysis for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 51: Rest of World Historic Review for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 52: Rest of World 15-Year Perspective for Diabetic Macular Edema Treatment by Product - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroid and Other Products for the Years 2012, 2021 & 2027
- IV. COMPETITION